Derivation of a score to predict infection due to multidrug-resistant Pseudomonas aeruginosa: a tool for guiding empirical antibiotic treatment
ABSTRACT: Objectives: Multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) constitutes an emerging health problem. A predictive score of MDR-PSA infection would allow an early adaptation of empirical antibiotic therapy. Methods: We performed a single-centre case-control (1:2) retrospective study including 100 patients with MDR-PSA and 200 with a non–MDR-PSA infection. Cases and controls were matched by site of infection, clinical characteristics and immunosuppression. A point risk score for prediction of MDR-PSA infection was derived from a logistic regression model. Secondary outcomes (clinical improvement, complications and discharge) were also compared. Results: Cases with MDR-PSA infection were younger than controls (67.5 vs. 73.0 y; P = 0.031) and have more frequent cirrhosis (9% vs. 2%; P = 0.005). Independent risk factors for MDR-PSA infection were prior antibiotic treatment (80% vs. 50.5%; P < 0.001), prior colonisation with MDR bacteria (41% vs. 13.5%; P < 0.001), hospital-acquired infection (63% vs. 47%; P = 0.009) and septic shock at diagnosis (33% vs. 14%; P < 0.001). Adequate therapy was less frequent in MDR-PSA infections (31% vs. 66.5% for empirical therapy; P < 0.001). The risk score included: previous MDR-PSA isolation (11 points), prior antibiotic use (3 points), hospital-acquired infection (2 points) and septic shock at diagnosis (2 points). It showed an area under the curve of 0.755 (95% CI: 0.70–0.81) and allowed to classify individual risk into various categories: 0–2 points (<20%), 3–5 points (25%–45%), 7–11 points (55%–60%), 13–16 points (75%–87%) and a maximum of 18 points (93%). Conclusion: Infections due to MDR-PSA have a poorer prognosis than those produced by non-MDR-PSA. Our score could guide empirical therapy for MDR-PSA when P. aeruginosa is isolated..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of Global Antimicrobial Resistance - 29(2022), Seite 215-221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pilar Hernández-Jiménez [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Case-control |
|---|
| doi: |
10.1016/j.jgar.2022.03.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ042801133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ042801133 | ||
| 003 | DE-627 | ||
| 005 | 20230308064331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jgar.2022.03.014 |2 doi | |
| 035 | |a (DE-627)DOAJ042801133 | ||
| 035 | |a (DE-599)DOAJdffa632f87314855801178f9a930f77c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Pilar Hernández-Jiménez |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Derivation of a score to predict infection due to multidrug-resistant Pseudomonas aeruginosa: a tool for guiding empirical antibiotic treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT: Objectives: Multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) constitutes an emerging health problem. A predictive score of MDR-PSA infection would allow an early adaptation of empirical antibiotic therapy. Methods: We performed a single-centre case-control (1:2) retrospective study including 100 patients with MDR-PSA and 200 with a non–MDR-PSA infection. Cases and controls were matched by site of infection, clinical characteristics and immunosuppression. A point risk score for prediction of MDR-PSA infection was derived from a logistic regression model. Secondary outcomes (clinical improvement, complications and discharge) were also compared. Results: Cases with MDR-PSA infection were younger than controls (67.5 vs. 73.0 y; P = 0.031) and have more frequent cirrhosis (9% vs. 2%; P = 0.005). Independent risk factors for MDR-PSA infection were prior antibiotic treatment (80% vs. 50.5%; P < 0.001), prior colonisation with MDR bacteria (41% vs. 13.5%; P < 0.001), hospital-acquired infection (63% vs. 47%; P = 0.009) and septic shock at diagnosis (33% vs. 14%; P < 0.001). Adequate therapy was less frequent in MDR-PSA infections (31% vs. 66.5% for empirical therapy; P < 0.001). The risk score included: previous MDR-PSA isolation (11 points), prior antibiotic use (3 points), hospital-acquired infection (2 points) and septic shock at diagnosis (2 points). It showed an area under the curve of 0.755 (95% CI: 0.70–0.81) and allowed to classify individual risk into various categories: 0–2 points (<20%), 3–5 points (25%–45%), 7–11 points (55%–60%), 13–16 points (75%–87%) and a maximum of 18 points (93%). Conclusion: Infections due to MDR-PSA have a poorer prognosis than those produced by non-MDR-PSA. Our score could guide empirical therapy for MDR-PSA when P. aeruginosa is isolated. | ||
| 650 | 4 | |a Multidrug resistance | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 4 | |a MDR-PSA | |
| 650 | 4 | |a Case-control | |
| 650 | 4 | |a Risk score | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Francisco López-Medrano |e verfasserin |4 aut | |
| 700 | 0 | |a Mario Fernández-Ruiz |e verfasserin |4 aut | |
| 700 | 0 | |a Jose T. Silva |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Corbella |e verfasserin |4 aut | |
| 700 | 0 | |a Rafael San-Juan |e verfasserin |4 aut | |
| 700 | 0 | |a María Ruiz-Ruigómez |e verfasserin |4 aut | |
| 700 | 0 | |a Manuel Lizasoain |e verfasserin |4 aut | |
| 700 | 0 | |a Isabel Rodríguez-Goncer |e verfasserin |4 aut | |
| 700 | 0 | |a Jazmín Díaz-Regañón |e verfasserin |4 aut | |
| 700 | 0 | |a Diego López-Mendoza |e verfasserin |4 aut | |
| 700 | 0 | |a Esther Viedma |e verfasserin |4 aut | |
| 700 | 0 | |a José María Aguado |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Global Antimicrobial Resistance |d Elsevier, 2021 |g 29(2022), Seite 215-221 |w (DE-627)DOAJ078609836 |x 22137173 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g pages:215-221 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jgar.2022.03.014 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/dffa632f87314855801178f9a930f77c |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2213716522000662 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2213-7165 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |h 215-221 | ||